Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

Phase 4

Recruiting

Conditions: Plaque, Atherosclerotic

Interventions: Drug: atorvastatin
Procedure: IVUS/OCT
Drug: inclisiran

First Posted Date: 2024-04-18

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 318

Registration Number: NCT06372925

Locations: 🇨🇳
Novartis Investigative Site, Harbin, Heilongjiang, China

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Ofatumumab

First Posted Date: 2024-04-03

Last Posted Date: 2024-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06345157

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Completed

Conditions: BRAF V600 Mutation Positive Melanoma

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT06337617

Locations: 🇨🇳
Novartis, Shanghai, China

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus, SLE

Interventions: Drug: PIT565

First Posted Date: 2024-03-28

Last Posted Date: 2025-01-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT06335979

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Phase 3

Recruiting

Conditions: Polymyalgia Rheumatica

Interventions: Biological: Secukinumab

First Posted Date: 2024-03-26

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06331312

Locations: 🇺🇸
Center for Rheumatology Research, West Hills, California, United States
🇺🇸
Sarasota Arthritis Research Center, Sarasota, Florida, United States
🇺🇸
Klein and Associates, Hagerstown, Maryland, United States

and more 4 locations

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: First-line Ribociclib + endocrine therapy
Drug: First-line endocrine therapy
Drug: First-line chemtherapy

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2610

Registration Number: NCT06311383

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus
Sjögrens Disease
Rheumatoid Arthritis

Interventions: Biological: VAY736 1ml PFS
Biological: VAY736 2ml AI
Biological: VAY736 2 ml PFS

First Posted Date: 2024-03-05

Last Posted Date: 2024-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT06293365

Locations: 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
Advanced Medical Research, La Palma, California, United States

and more 15 locations

Revolade Tablets Specified Drug-use Survey

Recruiting

Conditions: Aplastic Anemia

Interventions: Other: eltrombopag

First Posted Date: 2024-03-01

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT06287268

Locations: 🇯🇵
Novartis Investigative Site, Saitama, Japan

Specified Drug-use Survey of Leqvio for s.c. Injection.

Recruiting

Conditions: Hypercholesterolaemia
Familial Hypercholesterolaemia

Interventions: Other: inclisiran

First Posted Date: 2024-02-23

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 560

Registration Number: NCT06275724

Locations: 🇯🇵
Novartis Investigative Site, Yamagata, Japan

Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.

Completed

Conditions: Diffuse Large B-cell Lymphoma

First Posted Date: 2024-02-21

Last Posted Date: 2024-02-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 613

Registration Number: NCT06271369

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy